July 27, 2021
PeptiDream Inc.
Takeda Pharmaceutical Company Limited

PeptiDream and Takeda Expand Collaborative Research and License Agreement to Develop Peptide Drug Conjugates for CNS Diseases

- Expansion of existing partnership covering neuromuscular indications to now include CNS indications in neurodegeneration
- PeptiDream is eligible to receive up to approximately $3.5 billion in total, as upfront and potential preclinical / clinical / launch / sales-based milestones, excluding royalty payments

Partnerships in All Three Business Segments

PeptiDream



Note: Historical footprint for company's press releases related to new alliance / partnership agreement as of Dec 31, 2020.
Not including a press release about milestone achievement or progress for each program.

PDC programs Expanded programs

Progress of Programs in Drug Development Stages

	Drug Discovery				Clinical Development			
	Target Validation-to-Hit Stage	Hit-to-Lead Stage	Lead-to-GLP-Tox Stage	GLP-Tox-to-IND Stage	Phase 1	Phase 2	Phase 3	Total
As of December 31, 2019	43	43	11	8	2	0	0	107
As of December 31, 2020	39	58	13	8	2	0	0	120

Number of Programs for Each Drug Discovery Approach

PeptiDream

Hit peptides obtained through PDPS



PDPS Hits >> Optimization as drugs

PDPS Hits >> Crystal structure *In-Silico drug design*

PDPS Hits >> Combination with various payloads

		Number of programs
I	Peptide Drugs	81
II	Small Molecule Drugs	
III	Peptide Drug Conjugate (PDC)	39
	Total	120

Note: As of December 31, 2020

Strategic Collaboration with Biohaven (ex-Kleo Pharma)

Multiple programs against Multiple Myeloma (CD38-ARM™)

Mechanism of Action



KP1237 is a peptide-drug conjugate consisting of CD38-binding peptide and IgG antibody-binding compound. It recruits endogenous antibodies (IgG) to target cancer cells, which recruit immune cells to attack cancer cells.

CD38-ARM™ Pipeline

Program	Patient Population	Discovery	Validation/ Optimization	*In vivo* POC	IND Studies	Phase 1/2
1 KP1237 + Autologous NK cells	Post-Autologous Stem Cell Transplant (MRD+)					~2021 (under review)
2 KP1237	Daratumumab Recurrent/ Refractory					
3 KP1237 + Allogenic NK cells	Post-Allogenic Stem Cell Transplant (MRD+)					

Source: Created by PeptiDream, based on Biohaven (ex-Kleo Pharamaceuticals)'s materials

PDC (Peptide Drug Conjugates)

Unlocking the potential of a wide-range of payload combinations

PeptiDream

Carrier Peptide

Macrocyclic peptide selectively binding to target of interest



- Selective delivery of payload to target of interest
- Tunable pharmacokinetics and drug-peptide ratio by chemical modification
- Diverse payload combinations with simple straightforward linker chemistry

Payload (cargo)

Therapeutic and diagnostic compound

Protein

Antibody

Nucleic Acid



Peptide

Small Molecule



Radionuclide

Diagnostic RI

^{89}Zr

Therapeutic RI

^{225}Ac

Technological advantages of PDCs open up possibility of new applications and partnerships

PeptiDream



Strengthening In-house Pipeline through Selective Diversification of Strategic Alliances and Investments